GlassScriptPhysician profile
Henry H Hon
NPI 1134157837
$10,274.73
in general payments reported to CMS, 2019-2025
28 companies · $1,064 in 2025
The $1,064 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,901 · 2020: $888 · 2021: $1,444 · 2022: $1,124 · 2023: $2,368 · 2024: $1,485 · 2025: $1,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,342 · Travel and Lodging: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,342.12 |
| Travel and Lodging | $575.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,984.18 | 2021-2023 | Selectsecure, Micra, Linq II |
| Cvrx, INC. | $1,668.65 | 2020-2025 | Barostim Neo System |
| Abiomed | $1,454.21 | 2019-2024 | Impella |
| Kestra Medical Technology Services, INC. | $944.70 | 2023-2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $875.37 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $468.36 | 2020 | |
| Abbott Laboratories | $468.34 | 2019-2024 | Gallant, Aveir, Jot Dx |
| Biotronik INC. | $316.58 | 2019-2023 | Orsiro Mission, Recross |
| Boston Scientific Corporation | $245.08 | 2019-2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.92 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $237.81 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $226.62 | 2021-2024 | Lifevest |
| Pfizer INC. | $172.15 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $170.34 | 2022-2024 | Amvuttra, Onpattro |
| Amgen INC. | $146.13 | 2019-2024 | Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $115.61 | 2022 | |
| Astellas Pharma US INC | $109.73 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $91.79 | 2019 | |
| Sanofi-Aventis U.S. LLC | $72.50 | 2019 | |
| Heartflow, INC. | $66.16 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $44.19 | 2020-2024 | Farxiga |
| Chiesi USA, INC. | $37.37 | 2021-2025 | Kengreal |
| Bayer Healthcare Pharmaceuticals INC. | $25.21 | 2025 | |
| Irhythm Technologies, INC. | $23.13 | 2019 | |
| Scpharmaceuticals INC. | $19.91 | 2025 | |
| Agepha Pharma Fz LLC | $19.72 | 2025 | Lodoco |
| Lexicon Pharmaceuticals, INC. | $16.18 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Hon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.